Show simple item record

Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.

dc.contributor.authorPelzer, U
dc.contributor.authorBlanc, J
dc.contributor.authorMelisi, D
dc.contributor.authorCubillo, A
dc.contributor.authorVon Hoff, D
dc.contributor.authorWang-Gillam, A
dc.contributor.authorChen, L
dc.contributor.authorSiveke, J
dc.contributor.authorWan, Y
dc.contributor.authorSolem, C
dc.contributor.authorBotteman, M
dc.contributor.authorYang, Y
dc.contributor.authorde Jong, F
dc.contributor.authorHubner, Richard A
dc.date.accessioned2017-03-28T14:49:14Z
dc.date.available2017-03-28T14:49:14Z
dc.date.issued2016
dc.identifier.citationQuality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy. 2016, 39 260-260 Oncol Res Treaten
dc.identifier.urihttp://hdl.handle.net/10541/620223
dc.language.isoenen
dc.titleQuality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCharite-Universitatsmedizin, Berlin, Germanyen
dc.identifier.journalOncology Research and Treatmenten


This item appears in the following Collection(s)

Show simple item record